Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
This is an open label dose adjusted phase II trial of the oral farnesyltransferase inhibitor
(FTI) lonafarnib (SCH66336) for patients with HGPS and progeroid laminopathies.